Updated on 25 September 2013
The FDA had cancelled the discussion of sugammadex on July 18 and had advised Merck that the agency needed additional time to assess the results of the hypersensitivity study
Singapore: Merck received a complete response letter from the US FDA for the resubmission of the new drug application (NDA) for sugammadex sodium injection, Merck's investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.
The FDA's letter raised concerns about operational aspects of a hypersensitivity study that the agency had requested in 2008. Merck is evaluating the complete response letter and expects to be able to determine a path forward in the very near future.
"We believe sugammadex is an important innovation, and will work closely with the FDA to bring this product to hospitals, surgeons, anesthesia professionals and patients in the United States," said Dr David Michelson, head, global neuroscience clinical development, Merck Research Laboratories.
As previously disclosed, the FDA cancelled the discussion of sugammadex at the July 18th Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). At that time, the FDA advised Merck that the agency needed additional time to assess the results of the agency's recently completed inspection of a clinical trial site conducting the hypersensitivity study.
Neuromuscular blockade is used in anesthesiology to induce muscle relaxation during surgery. Sugammadex is designed to work by inactivating rocuronium or vecuronium, two neuromuscular blocking agents, directly by encapsulation. If approved, sugammadex would be the first in a new class of medicines, known as selective relaxant binding agents, to be used in the US. Sugammadex is currently marketed in more than 50 countries other than the US, and more than five million vials have been sold as of June 2013.